Healthcare Stocks in Focus: Rapport Therapeutics and Beyond Air Lead Gainers

Healthcare stocks experienced significant movements in Monday's intraday session. Gainers include Rapport Therapeutics, Beyond Air, Talphera, Acrivon Therapeutics, AlphaTON Capital, and Seres Therapeutics, which saw shares rise by up to 117.7%. Losers include CDT Equity, MEI Pharma, Summit Therapeutics, CERo Therapeutics Hldgs, NovaBay Pharmaceuticals, and Indaptus Therapeutics, which saw shares decline by up to 31.1%.

Healthcare stocks saw significant movements in Monday's intraday session, with notable gains and losses among various companies. Gainers included Rapport Therapeutics (RAPP), Beyond Air (XAIR), Talphera (TLPH), Acrivon Therapeutics (ACRV), AlphaTON Capital (ATON), and Seres Therapeutics (MCRB), with shares rising by up to 117.7%. Losers included CDT Equity (CDT), MEI Pharma (MEIP), Summit Therapeutics (SMMT), CERo Therapeutics Hldgs (CERO), NovaBay Pharmaceuticals (NBY), and Indaptus Therapeutics (INDP), with shares declining by up to 31.1%.

Rapport Therapeutics saw its shares increase by 117.7% to $31.26, with a market cap of $524.1 million [1]. Beyond Air's shares rose 60.62% to $3.55, with a market value of $11.5 million. Talphera's stock moved upwards by 28.36% to $0.7, with a market value of $11.2 million. Acrivon Therapeutics' shares rose 27.81% to $1.7, with a market value of $41.8 million. AlphaTON Capital's shares moved upwards by 25.73% to $6.4, with a market value of $11.5 million. Seres Therapeutics' shares moved upwards by 23.96% to $24.0, with a market value of $169.4 million.

CDT Equity's shares fell 31.1% to $0.81, with a market cap of $3.5 million. MEI Pharma's stock decreased by 28.14% to $3.04, with a market cap of $138.9 million. Summit Therapeutics' stock decreased by 24.74% to $19.55, with a market cap of $19.2 billion. CERo Therapeutics Hldgs' stock declined by 22.37% to $4.6, with a market value of $7.1 million. NovaBay Pharmaceuticals' stock fell 22.26% to $2.9, with a market cap of $21.7 million. Indaptus Therapeutics' shares fell 20.38% to $2.63, with a market cap of $3.6 million [1].

These movements reflect a mix of earnings optimism, clinical trial progress, and speculative positioning, driven by various catalysts. For instance, Seres Therapeutics' shares surged due to updates on its lead candidate SER-155 at the H.C. Wainwright 27th Annual Global Investment Conference [2]. TransMedics Group Inc. (TMDX) jumped 5.57% in after-hours trading, following the FDA's conditional approval of its Investigational Device Exemption for the Next-Generation OCS ENHANCE Heart trial [2]. Capricor Therapeutics Inc. (CAPR) rose 6.30% in after-hours trading, with the company announcing the dosing of the first subjects in a Phase 1 clinical trial for its novel exosome-based vaccine platform, StealthX [2].

In contrast, NovaBay Pharmaceuticals (NBY) saw a 17.54% surge in early September 2025, driven by a new CEO, special dividend, and $6M capital infusion from David E. Lazar [3]. The appointment of a new CEO and governance reforms aim to strengthen R&D pipelines and align stakeholder interests, boosting investor confidence temporarily. A $0.80/share dividend and Lazar's investment eased short-term liquidity risks but highlighted ongoing challenges like negative earnings and limited analyst coverage.

These movements underscore the dynamic nature of the healthcare sector, where companies' performances can be influenced by a variety of factors, from clinical trial results to leadership changes and market sentiment. Investors should closely monitor these developments and consider the specific risks and opportunities associated with each company.

References:
[1] https://www.benzinga.com/insights/movers/25/09/47553672/12-health-care-stocks-moving-in-mondays-intraday-session
[2] https://www.nasdaq.com/articles/biotech-stocks-surge-after-hours-capr-tmdx-lead-gains-amid-trial-updates-and-earnings
[3] https://www.ainvest.com/news/novabay-pharmaceuticals-soars-17-54-ceo-appointment-dividend-2509/